Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Lane

Showing results (241-250 of 257) with videos related to

Pageof 26
Sort By:
The Journal of Urology|November 28, 2019
Reply by AuthorsAndrea Minervini, Riccardo Campi, Brian R Lane, et al.
The Journal of Urology|August 14, 2023
Diabetes, Obesity, and Pathological Upstaging in Renal Cell Carcinoma: Results From a Large Multi-institutional ConsortiumDeepak K Pruthi, Gregor Miller, Donna P Ankerst, et al.
The Journal of Urology|October 9, 2023
Reply by AuthorsDeepak K Pruthi, Gregor Miller, Donna P Ankerst, et al.
Minerva Urology and Nephrology|March 29, 2022
Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International ConsortiumRiccardo Campi, Antonio A Grosso, Brian R Lane, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 4, 2021
Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal massesRiccardo Campi, Fabrizio Di Maida, Brian R Lane, et al.
European Urology|June 2, 2012
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trialA Karim Kader, Jielin Sun, Brian H Reck, et al.
Journal of Clinical Medicine|April 12, 2022
Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Surface-Intermediate-Base Margin Score Consortium)Fabrizio Di Maida, Riccardo Campi, Brian R Lane, et al.
Urologic Oncology|December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergencyJohn L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology|May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
The Lancet. Oncology|November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Pageof 26

Showing results (241-250 of 257) with videos related to

Sort By:
Pageof 26
The Journal of Urology|November 28, 2019
Reply by AuthorsAndrea Minervini, Riccardo Campi, Brian R Lane, et al.
The Journal of Urology|August 14, 2023
Diabetes, Obesity, and Pathological Upstaging in Renal Cell Carcinoma: Results From a Large Multi-institutional ConsortiumDeepak K Pruthi, Gregor Miller, Donna P Ankerst, et al.
The Journal of Urology|October 9, 2023
Reply by AuthorsDeepak K Pruthi, Gregor Miller, Donna P Ankerst, et al.
Minerva Urology and Nephrology|March 29, 2022
Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International ConsortiumRiccardo Campi, Antonio A Grosso, Brian R Lane, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 4, 2021
Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal massesRiccardo Campi, Fabrizio Di Maida, Brian R Lane, et al.
European Urology|June 2, 2012
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trialA Karim Kader, Jielin Sun, Brian H Reck, et al.
Journal of Clinical Medicine|April 12, 2022
Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Surface-Intermediate-Base Margin Score Consortium)Fabrizio Di Maida, Riccardo Campi, Brian R Lane, et al.
Urologic Oncology|December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergencyJohn L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology|May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
The Lancet. Oncology|November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Pageof 26